- •Foreword
- •Preface
- •Contents
- •Contributors
- •Introduction
- •Noninfectious Retinal Manifestations
- •Cytomegalovirus Retinitis
- •Necrotizing Herpetic Retinitis (by Varicella Zoster)
- •Toxoplasmic Retinochoroiditis
- •Syphilitic Uveitis, Papillitis, and Retinitis
- •Candida Vitritis and Retinitis
- •Pneumocystis carinii Choroiditis
- •Cryptococcus neoformans Chorioretinitis
- •Mycobacterium Choroiditis
- •B-Cell Lymphoma
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Etiologic Agent
- •Toxocara canis
- •Ancylostoma caninum
- •Baylisascaris procyonis
- •Trematodes
- •Mode of Transmission
- •Diagnosis and Pathogenesis
- •Early Stage
- •Late Stage
- •Ancillary Tests
- •Serologic Test
- •Fluorescein Angiography
- •Visual Field Studies
- •Scanning Laser Ophthalmoscopy (SLO)
- •Optic Coherence Tomography (OCT)
- •GDx® Nerve Fiber Analyzer
- •Differential Diagnosis
- •Management
- •Laser Treatment
- •Oral Treatment
- •Pars Plana Vitrectomy (PPV)
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Epidemiology
- •Etiology and Pathogenesis
- •Systemic Manifestations
- •Clinical Intraocular Manifestations
- •Diagnosis
- •Treatment
- •Surgical Technique
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Pathogenesis and Life Cycle
- •Clinical Manifestations
- •Epidemiology
- •Diagnosis
- •Differential Diagnosis
- •Management
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Current Epidemiology
- •Eyelid Tuberculosis
- •Conjunctival Tuberculosis
- •Scleral Tuberculosis
- •Phlyctenulosis
- •Corneal Tuberculosis
- •Uveal Tuberculosis
- •Anterior Uveitis
- •Intermediate Uveitis
- •Posterior Uveitis (Choroidal Tuberculosis)
- •Orbital Tuberculosis
- •Retinal Tuberculosis
- •Retinal Vascular Disease
- •Tuberculous Panophthalmitis
- •Neuro-ophthalmological Aspects
- •Ocular Tuberculosis Associated with Mycobacterium bovis
- •Rare Presentations
- •Isolated Macular Edema
- •Isolated Ocular Tuberculosis
- •Intraocular Infection with Pigmented Hypopyon
- •Ocular Tuberculosis After Corticosteroid Therapy
- •Systemic Investigations
- •Ocular Investigations
- •Corticosteroid Therapy
- •Antitubercular Therapy
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Pathogenesis
- •Clinical Manifestations
- •Epidemiology
- •Diagnosis
- •Differential Diagnosis
- •Management
- •Pyrimethamine
- •Sulfonamides
- •Folinic Acid
- •Clindamycin
- •Azithromycin
- •Trimethoprim and Sulfamethoxazole
- •Spiramycin
- •Atovaquone
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Bartonellosis
- •Epidemiology
- •Microbiology
- •Clinical Findings in Cat Scratch Disease
- •Systemic Manifestations
- •Ocular Manifestations
- •Parinaud’s Oculoglandular Syndrome (POGS)
- •Retinal and Choroidal Manifestations and Complications
- •Neuroretinitis (Leber’s Neuroretinitis)
- •Multifocal Retinitis and Choroiditis
- •Vasculitis and Vascular Occlusion
- •Peripapillary Bacillary Angiomatosis
- •Uveitis
- •Diagnosis
- •Biopsy and Testing
- •Therapy
- •Controversies and Perspectives
- •Clinical Pearls
- •Lyme Disease
- •Diagnosis
- •Ocular Manifestations
- •Intermediate Uveitis
- •Retinal Vasculitis, Branch Retinal Artery, Retinal Vein Occlusion, and Cotton-Wool Spots
- •Neuroretinitis
- •Other Ocular Manifestations
- •Cystoid Macular Edema and Macular Pucker
- •Retinal Pigment Epithelial Detachment
- •Retinitis Pigmentosa-Like Retinopathy
- •Choroidal Neovascular Membrane
- •Acute Posterior Multifocal Placoid Pigment Epitheliopathy-Like Picture
- •Retinal Tear
- •Ciliochoroidal Detachment
- •Therapy
- •Controversies and Perspectives
- •Clinical Pearls
- •Syphilis
- •Ocular Manifestations
- •Retina and Choroid
- •Retinal Vasculature
- •Optic Disk
- •Association Between HIV and Syphilis
- •Clinical Importance of Ocular Syphilis
- •Therapy
- •Controversies and Perspectives
- •Clinical Pearls
- •References
- •Introduction
- •Acute Retinal Necrosis
- •Causative Virus
- •Epidemiology
- •Virological Diagnosis
- •Clinical Course
- •Treatment
- •Cytomegalovirus
- •Diagnosis
- •Staging and Progression
- •Laboratory Findings
- •Treatment
- •Pharmacologic
- •Surgical
- •Patient Follow-up
- •Epidemiology
- •Diagnosis
- •HIV Disease
- •HIV Therapy
- •Ocular Manifestations of HIV
- •Progressive Outer Retinal Necrosis
- •Diagnosis
- •Etiology
- •Therapy
- •Rubella
- •West Nile Virus
- •Other Systemic Illnesses
- •Controversies and Perspectives
- •What Is the Best Surgical Approach for Repair of Secondary Retinal Detachment?
- •Focal Points
- •References
- •Introduction
- •Causative Organisms
- •Candidiasis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Aspergillus Retinitis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Cryptococcal Chorioretinitis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Coccidioides immitis Chorioretinitis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Histoplasma Chorioretinitis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Sporothrix schenckii Chorioretinitis
- •Risk Factors
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Treatment
- •Controversies and Perspectives
- •Focal Points
- •References
- •10: Endogenous Endophthalmitis
- •Introduction
- •Clinical Findings
- •Diagnosis
- •How to Culture
- •Polymerase Chain Reaction
- •Treatment
- •Systemic Antibiotics
- •Intravitreous Antibiotics
- •Corticosteroid Therapy
- •Vitrectomy
- •Prognosis
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Etiology
- •Genetic Features
- •Immunopathogenesis
- •Diagnosis
- •Posterior Segment Findings
- •Management
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Epidemiology
- •Prevalence and Incidence
- •Age of Onset
- •The Gender Factor
- •Etiopathogenesis
- •Clinical Features and Diagnosis
- •Ocular Involvement
- •Posterior Segment Involvement
- •Fluorescein Angiography
- •Indocyanine Green Angiography
- •Optical Coherence Tomography
- •Other Ocular Manifestations
- •Complications
- •Histopathology
- •Prognosis of Ocular Disease
- •Juvenile Behçet’s Disease
- •Pregnancy and Behçet’s Disease
- •Differential Diagnosis
- •Management of Ocular Disease
- •Medical Treatment
- •Colchicine
- •Corticosteroids
- •Intravitreal Triamcinolone
- •Cyclosporin A and Tacrolimus (FK506)
- •Anti-tumor Necrosis Factor Treatment
- •Cytotoxic and Other Immunosuppressive Agents
- •Tolerization Therapy
- •Laser Treatment
- •Plasmapheresis
- •Cataract Surgery
- •Trabeculectomy
- •Vitrectomy
- •Controversies and Perspectives
- •Pearls
- •References
- •13: Intraocular Lymphoma
- •Introduction
- •Historical Background
- •Epidemiology
- •Etiology
- •Imaging
- •Diagnosis and Pathology
- •Treatment
- •Controversies and Perspectives
- •Focal Points
- •Acknowledgments
- •References
- •14: Choroidal and Retinal Metastasis
- •Introduction
- •Primary Cancer Sites Leading to Intraocular Metastasis
- •Intraocular Metastasis Onset
- •Choroidal Metastases
- •Ciliary Body Metastases
- •Iris Metastases
- •Retinal Metastases
- •Optic Disk Metastases
- •Vitreous Metastases
- •Ocular Paraneoplastic Syndromes
- •Diagnostic Evaluation for Ocular Metastasis
- •Systemic Evaluation
- •Fluorescein Angiography
- •Indocyanine Green Angiography
- •Ultrasonography
- •Optical Coherence Tomography
- •Computed Tomography
- •Magnetic Resonance Imaging
- •Fine-Needle Aspiration Biopsy
- •Surgical Biopsy
- •Pathology of Ocular Metastasis
- •Observation
- •Radiotherapy
- •Surgical Excision, Enucleation
- •Patient Prognosis
- •Controversies and Perspective
- •Pearls
- •References
- •Introduction
- •CAR Cases
- •CAR Case 1: CAR Secondary to Esthesioneuroblastoma (Olfactory Neuroblastoma)
- •CAR Case 2: CAR Associated with Metastatic Breast Cancer
- •CAR Case 3: Paraneoplastic Optic Neuritis and Retinitis Associated with Small Cell Lung Cancer
- •Paraneoplastic Retinopathy: Melanoma-Associated Retinopathy (MAR)
- •MAR Case
- •Pearls
- •References
- •Introduction
- •Epidemiology
- •Pathophysiology
- •Clinical Presentation
- •Ulcerative Colitis
- •Crohn’s Disease
- •Ocular Manifestations
- •Posterior Segment Lesions
- •Treatment of Ocular Manifestations
- •Whipple’s Disease
- •Diagnosis
- •Extraintestinal Manifestations
- •Central Nervous System
- •Others
- •Treatment
- •Avitaminosis A
- •Pancreatitis
- •Familial Adenomatous Polyposis
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Demographics
- •Genetics
- •Fundus Manifestations
- •Management
- •Demographics
- •Genetics
- •Ophthalmologic Features
- •Fundus Manifestations
- •Management
- •Demographics
- •Genetics
- •Fundus Manifestations
- •Management
- •Genetics
- •Ophthalmologic Features
- •Fundus Manifestations
- •Management
- •Genetics
- •Fundus Manifestations
- •Management
- •Genetics
- •Fundus Manifestations
- •Controversies and Perspectives
- •References
- •Pathogenesis and Laboratory Findings
- •Innate Immune System Activation
- •Increased Availability of Self-antigen and Apoptosis
- •Adaptive Immune Response
- •Damage to Target Organs
- •General Clinical Findings
- •Ocular Symptoms
- •Posterior Ocular Manifestations
- •Mild Retinopathy
- •Vaso-occlusive Retinopathy
- •Lupus Choroidopathy
- •Anterior Visual Pathway
- •Posterior Visual Pathway
- •Oculomotor System
- •Anterior Ocular Manifestations
- •Drug-Related Ocular Manifestations
- •General Management
- •Controversies and Perspectives
- •Focal Points
- •References
- •19: Vogt–Koyanagi–Harada Disease
- •Introduction
- •History
- •Epidemiology
- •Immunopathogenesis
- •Histopathology
- •Immunogenetics
- •Clinical Features
- •Extraocular Manifestations
- •Ancillary Test
- •Fluorescein Angiography (FA)
- •Indocyanine Green Angiography (ICGA)
- •Cerebrospinal Fluid Analysis (CSF)
- •Ultrasonography (USG)
- •Ultrasound Biomicroscopy (UBM)
- •Magnetic Resonance Image (MRI)
- •Electrophysiology
- •Differential Diagnosis
- •Sympathetic Ophthalmia
- •Primary Intraocular B-Cell Lymphoma
- •Posterior Scleritis
- •Uveal Effusion Syndrome
- •Sarcoidosis
- •Lyme Disease
- •Treatment
- •Complications
- •Prognosis
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •General
- •Genetics
- •Pathogenesis
- •Ocular Pathology
- •Lens
- •Retina
- •Lens Subluxation
- •Clinical Findings
- •Pathogenesis
- •Differential Diagnosis
- •Treatment
- •Retinal Detachment
- •Clinical Findings
- •Pathogenesis
- •Therapy
- •Controversies and Perspectives
- •Focal Points
- •References
- •21: Diabetic Retinopathy
- •Introduction
- •Pathogenesis
- •Risk Factors
- •Duration of Disease
- •Glucose Control
- •Blood Pressure Control
- •Lipid Control
- •Other Factors
- •Proliferative Diabetic Retinopathy
- •Advanced Eye Disease
- •Diabetic Macular Edema
- •Management
- •Glycemic Control
- •Blood Pressure Control
- •Serum Lipid Control
- •Aspirin Treatment
- •Laser Photocoagulation
- •Vitrectomy
- •Pharmacotherapy
- •Corticosteroids
- •Triamcinolone Acetonide
- •Fluocinolone Acetonide
- •Extended-Release Dexamethasone
- •Pegaptanib
- •Ranibizumab
- •Bevacizumab
- •Controversies and Perspectives
- •Focal Points
- •References
- •Introduction
- •Hypertensive Retinopathy
- •Hypertensive Choroidopathy
- •Indirect Effects
- •Controversies and Perspectives
- •Summary
- •Focal Points
- •References
- •Introduction
- •Anemia
- •Aplastic Anemia
- •Hemoglobinopathies
- •Sickle Cell Disease
- •Thalassemia
- •Deferoxamine Toxicity
- •Autoimmune Hemolytic Anemia
- •Antiphospholipid Antibody Syndrome
- •Hemophilia and Platelet Disorders
- •Myelodysplastic Disorders
- •Myeloproliferative Disorders
- •Chronic Myelogenous Leukemia
- •Polycythemia Vera
- •Essential Thrombocythemia
- •Leukemias
- •Acute Myeloid Leukemia
- •Lymphoid
- •Lymphomas
- •B Cell Lymphoma
- •Hodgkin’s Lymphoma
- •Plasma Cell Disorders
- •Plasmacytoma/Multiple Myeloma
- •Plasma Cell Leukemia
- •T Cell Lymphomas
- •Controversies/Perspectives
- •Roth Spots
- •Anti-VEGF Therapy
- •Focal Points
- •Anemia
- •Hemoglobinopathies
- •Myelodysplastic Syndrome
- •Myeloproliferative Neoplasms
- •Leukemia
- •Lymphoma
- •References
- •24: The Ocular Ischemic Syndrome
- •Introduction
- •Demography
- •Etiology
- •Symptoms
- •Loss of Vision
- •Amaurosis Fugax
- •Pain
- •Visual Acuity
- •Signs
- •External
- •Anterior Segment Changes
- •Posterior Segment Findings
- •Diagnostic Studies
- •Fluorescein Angiography
- •Electroretinography
- •Carotid Artery Imaging
- •Others
- •Systemic Associations
- •Differential Diagnosis
- •Treatment
- •Systemic Therapy: Carotid Artery
- •Ophthalmic Therapy
- •Controversies and Perspectives
- •Focal Points
- •References
- •25: Ocular Manifestations of Pregnancy
- •Introduction
- •Physiologic Changes
- •Intraocular Pressure
- •Cornea
- •Pathologic Conditions
- •Pregnancy-Induced Hypertension
- •Clinical Features
- •Ocular Manifestations
- •HELLP Syndrome
- •Management of PIH
- •Prognosis
- •Central Serous Retinopathy
- •Occlusive Vascular Disorders
- •Purtscher’s-Like Retinopathy
- •Disseminated Intravascular Coagulation (DIC)
- •Thrombotic Thrombocytopenic Purpura (TTP)
- •Amniotic Fluid Embolism
- •Preexisting Conditions
- •Diabetic Retinopathy
- •Progression
- •Factors Associated with Progression
- •Pathophysiology of Progression
- •Treatment Criteria for Diabetic Retinopathy
- •Follow-up Guidelines
- •Intraocular Tumors
- •Uveal Melanoma
- •Choroidal Osteoma
- •Choroidal Hemangioma
- •Ocular Medications
- •Topical Drops
- •Diagnostic Agents
- •Summary
- •Focal Points
- •References
- •Introduction
- •Toxicity with Diffuse Retinal Changes
- •Toxicity with Pigmentary Degeneration
- •Quinolines
- •Phenothiazines
- •Deferoxamine
- •Toxicity with Crystalline Deposits
- •Tamoxifen
- •Canthaxanthine
- •Toxicity Without Fundus Changes
- •Cardiac Glycosides
- •Phosphodiesterase Inhibitors
- •Toxicity with Retinal Edema
- •Methanol
- •Toxicity with Retinal Vascular Changes
- •Talc
- •Oral Contraceptives
- •Interferon
- •Toxicity with Maculopathy
- •Niacin
- •Sympathomimetics
- •Toxicity with Retinal Folds
- •Sulfanilamide-Like Medications
- •Summary
- •Focal Points
- •References
- •Introduction
- •Diabetes
- •Vascular Disease
- •Hypertensive Retinopathy
- •Hypertensive Optic Neuropathy
- •Thrombotic Microangiopathy
- •Dysregulation of the Alternative Complement Pathway with Renal and Ocular Fundus Changes
- •Papillorenal Syndrome
- •Ciliopathies
- •Senior-Loken Syndrome and Related Syndromes with Nephronophthisis
- •Other Rare Metabolic Diseases
- •Congenital Disorders of Glycosylation (CDG)
- •Cystinosis
- •Fabry Disease
- •Peroxisomal Diseases: Refsum Disease
- •Neoplastic Diseases with Kidney and Ocular Involvement
- •von Hippel-Lindau Disease
- •Light Chain Deposition Disease
- •Controversies and Perspectives
- •Focal Points
- •References
- •Index
25 Ocular Manifestations of Pregnancy |
475 |
|
|
required, then nasolacrimal sac occlusion should be performed to limit the systemic absorption of the medication.
Diagnostic Agents
Fluorescein dye crosses the placenta and is present in breast milk for at least 3 days after administration [62]. No teratogenic or embryocidal effects have been reported in animals [63, 64]. Also, no adverse effects have been reported in humans. Halperin and coworkers reviewed the use of fluorescein angiography in pregnant patients [65]. A retrospective study of neonatal outcomes in 105 pregnant patients who underwent fluorescein angiography revealed that there was not a high rate of birth anomalies or complications. Nonetheless, most vitreoretinal specialists likely would avoid obtaining an angiogram during pregnancy unless a sight-threatening lesion, such as a choroidal neovascular membrane, is suspected.
Indocyanine green (ICG) has been used in pregnant women for non-ophthalmic purposes, such as for measuring hepatic blood flow, without adverse effect on the mother or fetus. It does not cross the placenta, and it is not known whether it is present in breast milk [66]. Fineman and coworkers conducted a survey of 1,101 members of the Retina, Macula, and Vitreous Societies regarding the use of ICG in pregnant women [67]. The survey revealed that there is widespread hesitation to use ICG for retinal angiography in pregnant women, despite its documented safety when used for non-ophthalmic purposes.
Summary
Pregnancy may be associated with a variety of ocular manifestations. The majority of these changes resolve after pregnancy, though occasionally, they may lead to permanent visual impairment. An understanding of these changes will help to establish the diagnosis as well as to plan the optimum treatment regimen when evaluating the pregnant female.
Focal Points
•Hypertensive-related conditions are the most commonly encountered abnormalities during pregnancy (pregnancy-induced hypertension, preeclampsia, eclampsia, HELLP syndrome).
•Pregnancy may exacerbate preexisting conditions, particularly diabetes mellitus, or may cause new conditions to arise such as central serous choroidopathy.
•A variety of vascular occlusive disorders may rarely be encountered (DIC, TTP).
References
1. Sunness JS. The pregnant woman’s eye. Surv Ophthalmol. 1988;32:219–38.
2. Philips CI, Gore SM. Ocular hypotensive effect of late pregnancy with and without high blood pressure. Br J Ophthalmol. 1985;69:117–9.
3.Paterson GL, Miller SJH. Hormonal influences in simple glaucoma. Br J Ophthalmol. 1963;47:129–37.
4.Wilke L. Episcleral venous pressure and pregnancy. Acta Ophthalmol (Copen). 1975;125(Suppl):40–41.
5. Horven I, Gjonnaess H, Kroese A. Corneal indentation pulse and intraocular pressure in pregnancy. Arch Ophthalmol. 1974;91:92–8.
6. Riss B, Riss P. Corneal sensitivity in pregnancy. Ophthalmologica. 1981;183:57–62.
7. Weinreb RN, Lu A, Beeson C. Maternal corneal thickness during pregnancy. Am J Ophthalmol. 1988;105: 258–60.
8. Park SB, Lindahl KJ, Temnycky GO, Aquavella JV. The effect of pregnancy on the corneal curvature. CLAO J. 1992;18:256–9.
9.Millodot M. The influence of pregnancy on the sensitivity of the cornea. Br J Ophthalmol. 1977;61: 646–9.
10. Fatt I, Harris MG. Refractive index of the cornea as a function of its thickness. Am J Optom Physiol Opt. 1973;50:383–6.
11.Schreyer P, Tzadok J, Sherman DJ, et al. Fluorescein angiography in hypertensive pregnancies. Int J Gynecol Obstet. 1990;34:127–32.
12.Jaffe G, Schatz H. Ocular manifestations of preeclampsia. Am J Ophthalmol. 1987;103:309–15.
13.Fry WE. Extensive bilateral retinal detachment in eclampsia with complete reattachment. Arch Ophthalmol. 1929;1:609–14.
14.Hallum AV. Eye changes in hypertensive toxemia of
pregnancy. JAMA. 1936;106:1649–51.
15. Valluri S, Adelberg D, Curtis R, et al. Diagnostic indocyanine green angiography in preeclampsia. Am J Ophthalmol. 1996;122:672–7.
476 |
D. Kuhl et al. |
|
|
16.Saito Y, Tano Y. Retinal pigment epithelial lesions associated with choroidal ischemia in preeclampsia. Retina. 1998;18:103–8.
17.Fry WE. Extensive bilateral retinal detachment in eclapmsia with complete retinal detachment. Arch Ophthalmol. 1929;1:609–614.
18. Beck RW, Gamel JW, Willcourt RJ, Berman G. Acute ischemic optic neuropathy in severe preeclampsia. Am J Ophthalmol. 1980;90:342–6.
19.Grimes DA, Ekbladh LE, McCartney WH. Cortical blindness in preeclampsia. Int J Gynaecol Obstet. 1980;17:601–3.
20.Beeson JH, Duda EE. Computed axial tomography scan demonstration of cerebral edema in eclampsia preceded by blindness. Obstet Gynecol. 1982;60:529–32.
21.Gupta LY, Mansour SE. Bilateral bullous retinal detachment as a complication of the HELLP syndrome. Can J Ophthalmol. 1994;29:242–5.
22. Leff SR, Yarian DL, Masciulli L, et al. Vitreous haemorrhage as a complication of HELLP syndrome. Br J Ophthalmol. 1990;74:498–9.
23.Cunningham FG, MacDonald PC, Gant NF, et al. Hypertensive disorders in pregnancy. In: Williams obstetrics. 19th ed. Norwalk: Appleton & Lange; 1993. p. 764–5.
24.Sunness JS, Haller JA, Fine SL. Central serous retinopathy and pregnancy. Arch Ophthalmol. 1993;111:360–4.
25.Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77:158–60.
26.Fastenberg DM, Ober RR. Central serous choroidopathy in pregnancy. Arch Ophthalmol. 1983;101:1055–8.
27.Gass JDM. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol. 1991;109:677–81.
28. Blodi BA, Johnson MW, Gass JDM, et al. Purtscher’s- like retinopathy after childbirth. Ophthalmology. 1990;97:1654–959.
29.Cogan D. Ocular involvement in disseminated intravascular coagulopathy. Arch Ophthalmol. 1975;93:1–8.
30.Hoines J, Buettner H. Ocular complications of disseminated intravascular coagulation (DIC) in abruptio placenta. Retina. 1989;9:105–9.
31.Amarosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1962;45:139–59.
32.Percival SP. The eye and Moschcowitz’s disease (thrombotic thrombocytopenic purpura): a review of 182 cases. Trans Ophthalmol Soc UK. 1970;90:375–82.
33.Lewellen DR, Singerman LJ. Thrombotic thrombocytopenic purpura with optic disk neovascularization, vitreous hemorrhage, retinal detachment, and optic
atrophy. Am J Ophthalmol. 1980;89:840–4.
34. Gum KB, Carter KD, Vine AK. Massive bilateral retinal vascular occlusion secondary to thrombocytopenic purpura. Retina. 1988;8:185–7.
35.Power MH, Regillo MC, Custis PH. Thrombotic thrombocytopenic purpura associated with purtscher retinopathy. Arch Ophthalmol. 1997;115:128–9.
36.Chang M, Herbert W. Retinal arteriolar occlusions following amniotic fluid embolism. Ophthalmology. 1984;91:1634–7.
37. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34–40.
38. Axer-Seigel R, Hod M, Fink-Cohen S, et al. Diabetic retinopathy during pregnancy. Ophthalmology. 1996;103:1815–9.
39. Phelps RL, Sakol P, Metzger BE, et al. Changes in diabetic retinopathy during pregnancy. Arch Ophthalmol. 1986;104:1806–10.
40. Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol. 1982;93:745–56.
41.Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. Br J Ophthalmol. 1997;81:249–51.
42. Sinclair SH, Nesler C, Foxman B, et al. Macular edema and pregnancy in insulin-dependent diabetes. Am J Ophthalmol. 1984;97:154–67.
43. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. Diabetes Care. 1995;18:631–7.
44. Lauszus F, Klebe JG, Bek T. Diabetic retinopathy in pregnancy during tight metabolic control. Acta Obstet Gynecol Scand. 2000;79:367–70.
45.Sinclair SH, Nesler CL, Schwartz SS. Retinopathy in the pregnant diabetic. Clin Obstet Gynecol. 1985;28:536–52.
46.Kitzmiller JL, Main E, Ward B, et al. Insulin lispro and the development of proliferative diabetic retinopathy
during pregnancy. Diabetes Care. 1999;22:874–6.
47. Chen HC, Newsom RS, Patel V, et al. Retinal blood flow changes during pregnancy in women with diabetes. Invest Ophthalmol Vis Sci. 1994;35:3199–208.
48. Schocket LS, Grunwald JE, Tsang AF, et al. The effects of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol. 1999;128:477–84.
49.The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. Arch Ophthalmol. 1979;97:654–5.
50.Stoessel KM, Liao PM, Thompson JT, Reece AE. Diabetic retinopathy and macular edema in pregnancy. Ophthalmology. 1991;98(suppl):146.
51.The American Academy of Ophthalmology. Diabetic retinopathy. Preferred practice patterns, vol. 13. San Francisco:TheAmericanAcademyofOphthalmology; 1998. p. 28.
52.Siegel R, Ainslie WH. Malignant ocular melanoma
during pregnancy. JAMA. 1963;185:542–3.
53. Seddon JM, MacLaughlin DT, Albert DM, et al. Uveal melanomas presenting during pregnancy and the investigation of oestrogen receptors in melanomas. Br J Ophthalmol. 1982;66:695–704.
54. Shields C, Shields J, Eagle R, et al. Uveal melanoma and pregnancy. Ophthalmology. 1991;98:1667–73.
55.McLeod BK. Choroidal osteoma presenting during pregnancy. Br J Ophthalmol. 1988;72:612–4.
56.Gass JDM. Stereoscopic atlas of macular diseases: a funduscopic and angiographic presentation. 4th ed. St. Louis: CV Mosby; 1997. p. 218–9.
57.Pitta C, Bergen R, Littwin S. Spontaneous regression of a choroidal hemangioma following pregnancy. Am J Ophthalmol. 1979;11:772–4.
25 Ocular Manifestations of Pregnancy |
477 |
|
|
58.Sunness JS. Pregnancy and the eye. Ophthalmol Clin North Am. 1992;5:623–40.
59.Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. Am J Ophthalmol. 1988;106:616–23.
60.Blaul G. Lokale betablocker wahrend der graviditat. Klin Monbl Augenheilkd. 1981;179:128–9.
61.Lustgarten JS, Podos SM. Topical timolol and the nursing mother. Arch Ophthalmol. 1983;101:1381.
62.Mattern J, Mayer PR. Excretion of fluorescein into breast milk. Am J Ophthalmol. 1990;109:598–9.
63.McEnerney JK, Wong WP, Peyman GA. Evaluation of the teratogenicity of fluorescein sodium. Am J Ophthalmol. 1977;84:847–50.
64. Salem H, Loux JJ, Smith S, Nichols CW. Evaluation of the toxicologic and teratogenic potentials of sodium fluorescein in the rat. Toxicology. 1979;12:143–50.
65. Halperin LS, Olk RJ, Soubrane G, Coscas G. Safety of fluorescein angiography during pregnancy. Am J Ophthalmol. 1990;109:563–6.
66.Rudolf H, Goretzlehner G, Brugmann E, et al. Assessment of liver function using indocyanine green (Ujoviridin) during normal pregnancy, during labor and in puerperium (in German). Zentralbl Gynakol. 1977;99:1548–53.
67.Fineman MS, Maguire JI, Fineman SW, Benson WE. Safety of indocyanine green angiography during pregnancy. Arch Ophthalmol. 2001;119:353–5.